In breast cancer, several studies have shown that a higher presence of TILs, particularly in triple-negative breast cancer (TNBC) and HER2-positive subtypes, is associated with a better response to chemotherapy and targeted therapies. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.